Management of cardiovascular risk in patients with multiple myeloma

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

(2018) Heinz Ludwig et al.   LEUKEMIA

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

(2017) L Rosiñol et al.   LEUKEMIA

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

(2017) Kyriaki Tzogani et al.   ONCOLOGIST

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

(2016) Ajai Chari et al.   BMC CANCER

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials

(2016) Don Robinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management of Carfilzomib-Associated Cardiac Adverse Events

(2016) Joseph Mikhael   Clinical Lymphoma Myeloma & Leukemia

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN JOURNAL OF HEART FAILURE

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

(2016) R Hájek et al.   LEUKEMIA

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload

(2015) Mark J. Ranek et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Role of Radiation Therapy for Multiple Myeloma

(2015) Giampaolo Talamo et al.   Frontiers in Oncology

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

(2014) M.-V. Mateos et al.   BLOOD

Update on treatment of light chain amyloidosis

(2014) S. Mahmood et al.   HAEMATOLOGICA

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

(2014) Lenka Kubiczkova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation

(2013) Abhishek Singla et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy

(2013) Jonathan L. Kaufman et al.   Clinical Lymphoma Myeloma & Leukemia

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

(2013) Ron T Gansevoort et al.   LANCET

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

International Myeloma Working Group recommendations for global myeloma care

(2013) H Ludwig et al.   LEUKEMIA

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

(2012) G. Curigliano et al.   ANNALS OF ONCOLOGY

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Cardiac Amyloidosis

(2012) C. Cristina Quarta et al.   CIRCULATION

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Melphalan-Induced Supraventricular Tachycardia: Incidence and Risk Factors

(2011) Victor Feliz et al.   CLINICAL CARDIOLOGY

How to Manage Neutropenia in Multiple Myeloma

(2011) Antonio Palumbo et al.   Clinical Lymphoma Myeloma & Leukemia

Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure

(2010) ZiMian Wang et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

(2010) D. Bovelli et al.   ANNALS OF ONCOLOGY

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage

(2010) Carrie Anna Geisberg et al.   CURRENT HYPERTENSION REPORTS

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

(2010) Sundar Jagannath et al.   LEUKEMIA RESEARCH

The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs

(2009) Ali Yazdanyar et al.   CLINICS IN GERIATRIC MEDICINE

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes

(2008) Jiahao Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Intracellular Protein Aggregation Is a Proximal Trigger of Cardiomyocyte Autophagy

(2008) Paul Tannous et al.   CIRCULATION

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE